A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)

PHASE2RecruitingINTERVENTIONAL

Enrollment

165

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

July 22, 2027

Conditions

Metabolic Dysfunction-associated Steatohepatitis (MASH)

Interventions

DRUG

Placebo

Placebo administered subcutaneously (SC) once a week.

DRUG

IBI362

IBI362 administered subcutaneously (SC) once a week.

Trial Locations (1)

RECRUITING

Beijing Tsinghua Changgung Hospital, Beijing

All Listed Sponsors

lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT06937749 - A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) | Biotech Hunter | Biotech Hunter